logo
  

Telia Co. Posts Profit In Q2

Swedish telecom company Telia Co. AB (0H6X.L,TLSNY.PK) Wednesday reported a huge profit for the second quarter, reflecting a capital gain from Telia Carrier, with a modest 0.5 percent growth in net sales. The Group also reiterated its service revenues and EBITDA growth outlook for 2021.

For the second quarter, the Group posted total income of 8.10 billion Swedish kronor, compared to last year's total loss of 2.03 billion Kronor. The results mainly included a capital gain from Telia Carrier, while last year's reflected an impairment of Turkcell Holding.

Adjusted EBITDA for the quarter slid by 0.1 percent to 7.731 billion kronor, while like-for-like adjusted EBITDA increased by 1.9 percent.

Quarterly net sales edged up 0.5 percent to 21.9 billion kronor from 21.8 billion kronor, and like for like net sales increased 4.9 percent. Service revenues slid by 1.3 percent to 18.9 billion kronor, while like for like service revenues increased 3.2 percent.

Based on the performance in the quarter, the Group said it is reiterating its full year outlook of service revenues and EBITDA, excluding Telia Carrier and FX, at flat to low single digit growth.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
RELATED NEWS
Follow RTT